Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by
educational grants from
AstraZeneca, Daiichi Sankyo, and Seattle Genetics
Breast Cancer is the most common cancer found in women, regardless
of race or ethnicity. According to the National Cancer Institute, an
estimated 231,840 new cases of invasive breast cancer are to be
diagnosed in women in the United States during 2020. The incidence
in women in the United States is 1 in 8 (about 12 percent). About
40,290 women are expected to die from breast cancer this year,
though death rates have been steadily decreasing over the past 20
years due to new and ever improving treatment options. HER2-positive
breast cancer is a breast cancer that tests positive for a protein
called human epidermal growth factor receptor 2 (HER2). This protein
promotes the growth of cancer cells. In about 1 of every 5 breast
cancers, the cancer cells have extra copies of the gene that makes
the HER2 protein. HER2-positive breast cancers tend to be more
aggressive than other types of breast cancer. Additionally, in the
later stages of HER2+ disease, when distant metastases are present,
cure becomes less likely and few patients are rendered free of
disease. Therapy in the HER2+ metastatic setting then focuses on
prolonging life and managing disease-and treatment-related adverse
events. Treatment selection must be individualized based upon
patient- and tumor-specific factors, as well as safety and efficacy
profile of available agents, with an emphasis on the combined goals
of tumor control, prolonged survival, and maintenance of patient
quality of life.
Fortunately for patients with HER2-positive advanced breast cancer,
several new agents have been recently approved. They have shown the
ability to improve safety and efficacy outcomes in the approximately
40% of patients living with HER2-positive advanced breast cancer.
With these options entering the treatment paradigm, it is critical
to provide medical directors, oncologists, practicing physicians and
others on the interprofessional management team with updated
clinical data and strategies on these new therapies the changing
treatment paradigm, with the ultimate goal of improving patient
Upon completion of this
activity, participants will be able to:
Analyze the efficacy and safety
profiles and recent clinical trial data of new and emerging
therapies, including tyrosine kinase inhibitors, for the
treatment of HER2-positive advanced breast cancer
Assess the role of emerging
therapies in the management of HER2-positive advanced breast
cancer who have failed two or more lines of therapy and have
Apply evidence-based approaches in
therapeutic decision-making for difficult-to-treat patient
populations with HER2-positive advanced breast cancer, including
sequencing and combination therapies
Integrate strategies to optimize
treatment decisions for patients with recurrent HER2-positive
advanced breast cancer
Examine strategies for anticipating,
recognizing, and managing adverse events of new and emerging
therapies, including tyrosine kinase inhibitors, in
HER2-positive advanced breast cancer
Discuss the managed care
considerations of new and emerging therapies, including tyrosine
kinase inhibitors, by exploring where these agents fit into
current HER2-positive advanced breast cancer management paradigm
||Sara Hurvitz, MD
Associate Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
Department of Medicine
David Geffen School of Medicine at UCLA
has received grants/research support from Ambrx, Amgen,
Bayer, Daiichi-Sankyo, Dignitana, Genentech/Roche, GSK,
Immunomedics, Lilly, Macrogenics, Merrimack, Novartis,
Pfizer, OBI Pharma, Pieris, PUMA, Radius, Sanofi,
Seattle Genetics, and Zymeworks. She has recieved
editorial support from Pfizer and Roche. Her
presentation has been reviewed for any bias.
MD has no real or perceived financial relationships to
Jeremy Williams has no real or perceived financial
relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived
financial relationships to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
This activity is supported by educational grants from
AstraZeneca, Daiichi Sankyo, and Seattle Genetics
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue